AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 31 min read$AUPH

TANG KEVIN purchased $12.5M of AUPH (indirect holdings)

TANG KEVIN (Chief Executive Officer) purchased 814,606 indirectly-held shares of Aurinia Pharmaceuticals Inc. (AUPH) at an average of $15.29 ($15.28–$15.35, $12.46M total) across 5 trades over 2026-05-29 to 2026-06-02. Filed jointly with TANG CAPITAL MANAGEMENT LLC (10% owner).

Original reporting
SEC EDGAR · TANG KEVIN, TANG CAPITAL MANAGEMENT LLC
Published Jun 3, 2026, 1:54 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AUPH
Bullish
high confidence
Mentioned
$AUPH
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AUPHBullishMed
01

Why it matters

The purchase adds to the CEO's ownership, suggesting confidence and may influence short‑term price dynamics.

02

Market read

First‑report insider buy of $12.5M could prompt short‑term buying interest in AUPH.

03

What to watch

Potential upcoming clinical data releases that could be driving the purchase.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$AUPHBullishHigh confidence
Context

CEO Kevin Tang bought 814,606 shares for $12.5M, increasing his stake to over 13M shares.

Expected impact

likely upward pressure as market prices in the insider buy.

Evidence & confidence

Form 4 filing is a primary source; the $12.5M purchase by the CEO is material for a micro‑cap biotech.

Market effects

Sector

May lift sentiment in the biotech sector as insider confidence is viewed positively.

Regional

Limited to US markets where AUPH trades.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

Insider buying could be a window‑dressing move; fundamentals remain uncertain.

Key entities

  • person
    Kevin Tang

    Chief Executive Officer of Aurinia Pharmaceuticals

  • company
    Aurinia Pharmaceuticals Inc.

    Biotech firm listed on Nasdaq under ticker AUPH

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AUPH insider trading history →

Related articles

SEP 17
$AUPHMed

Aurinia Stock Jumps After Earnings Beat And Pipeline Progress

Aurinia Pharmaceuticals reported Q2 revenue of $83.2M and net income of $37.4M, with LUPKYNIS sales at $79.4M. The company initiated new clinical studies for aritinercept. Analysts forecast revenue of $453.5M and earnings of $169.9M by 2029, with a 7% upside potential. The stock rose on earnings beat and pipeline progress.

simplywall.st2 min
SEP 16
$AUPHMed

Aurinia’s (AUPH) Profits Surge While Its One Drug Just Got Company

Aurinia Pharmaceuticals reported Q2 revenue of $83.2M, up 19%, and net income of $37.4M, up 74%. LUPKYNIS sales rose 19% to $79.4M. The company reiterated 2026 guidance and initiated a new Phase 4 study. R&D spending doubled, and tax expenses increased significantly. Cash reserves grew to $443.1M, despite a $74.9M share buyback.

yahoo.com2 min
AUG 21
$MRNAHighAI 9/10

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.

pro.thestreet.com3 min
AUG 20
$AUPHMed

Aurinia Pharmaceuticals (AUPH) Secures Patent Settlement With Teva, Blocking Lupkynis Generic Until 2036

Aurinia Pharmaceuticals (AUPH) settled a patent dispute with Teva (TEVA), delaying a generic version of Lupkynis until 2036. The deal boosted AUPH shares by 7%. Aurinia also settled with Sun Pharma in 2023 and faces ongoing litigation with other generics makers. Lupkynis is Aurinia's sole marketed drug, with H1 2026 revenue up 21% YoY to $161M, and full-year guidance of $315M-$325M.

londoninsider.co.uk2 min
AUG 20
$AUPHMed

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

Aurinia Pharmaceuticals settled patent litigation with Teva, pushing back potential generic competition for voclosporin until 2036. Aurinia's stock rose 6% on the news. Lupkynis, Aurinia's voclosporin product, recorded $153M in sales in H1 2026, up 21% YoY. Aurinia's patent litigation with other companies continues.

zacks.com2 min